News
Media contact:
Clément Robijns | c.robijns@biocom.de | +49-30-264 921-58
CARB-X (part of Boston University) announces the renewal of its support from Wellcome Trust, a worldwide…
The availability of surveillance data on antimicrobial resistance (AMR) makes it possible to assess incidence rates…
A new study by BD (Becton Dickinson) and MSD (Merck & Co.) found higher rates of…
With the goal of counteracting the growing world-wide crisis over resistance to antibiotics, the United Kingdom…
The recently published report by Boston Consulting Group, prepared together with World Economic Forum, Wellcome Trust,…
FasterCures and Financial Innovations Labs® have joint forces on a project to identify new financing models to…
ArrePath announced that it has raised $20 million in seed financing to advance its proprietary, machine…
BIO has published a new report that takes a closer look at the recent investment into…
BWC0977, Bugwork’s candidate for a novel broad spectrum anti-bacterial agent, will be further developed with financial…
The AMR Action Fund has moved into its new European office in Basel. The venture fund…
The AMR Action Fund has named several experts as members of its Scientific Advisory Board (SAB).…
Mutabilis, based in Romainville, France, announced that it has closed the deal on a Research Collaboration…
BEAM Alliance has released a new position paper outlining five pillars for an effective AMR pull…
By using its AI-based system AlphaFold British company DeepMind has added the predicted proteome of almost…
A total of four ventures, three from Germany and one from Finland, have been selected by…
The German government has released its policy priorities for the G7 Presidency in 2022 and confirmed…
Just recently, NIAID and BARDA both have published requests for proposals for the areas of therapeutics…
At least 1.27 million deaths per year are directly attributable to AMR, says a new study…
Within the framework of the ERA-NET JPIAMR-ACTION, JPIAMR (Joint Programming Initiative on Antimicrobial Resistance) is launching…
As of recently, collaborative research between ETH Zürich, University Hospital Basel, and the University of Basel…
Don’t miss to participate in the start-up competition @AMR conference supported by INCATE. Early-stage ventures fighting drug…
The WHO has released a new report analyzing the current antibacterial pipeline. It has been published…
Approximately 700,000 people are estimated to die due to infection by antibiotic-resistant bacteria every year, with…
By combining preventive, diagnostic, therapeutic and economic approaches for the first time the ARPEGE consortium led…
CARB-X Chief Scientist Dr. Richard Alm joins host Steven Yang for this episode of The Phage…
In December, a consortium of 8 public and 4 private Swiss institutions has joined forces to…
Pharma company Roche is among the partners of AMR-focused incubator INCATE. We spoke with Rusudan Okujava…
With US$361 million awarded to 92 projects funding, CARB-X closed the fifth fiscal year since inception.…
In late December, FIND announced an investment of US$21 million to accelerate the development, manufacturing, and…
Diagnostics company Ares Genetics GmbH, developing NGS- and AI-powered solutions to combat AMR, has successfully completed…
The G7 Finance Ministers have released a statement on actions to support antibiotic development, with the goal…
The UN Food and Agriculture Organization BioNTFAO has issued an Action Plan spanning a total of…
On the occasion of the World Antibiotic Awareness Week (WAAW), BEAM Alliance has published a series…
BEAM Alliance is among the partners of AMR-focused incubator INCATE. We spoke with Marc Gitzinger, CEO…
Together with the International Development Research Center (IDRC), the Global AMR R&D Hub published a new…
The Boehringer Ingelheim Venture Fund is among the industry partners of AMR-focused incubator INCATE. We spoke…
The Japanese pharma company Shionogi is among the industry partners of AMR-focused incubator INCATE. We spoke…
BioNTech SE has acquired PhagoMed GmbH, an Austrian start-up for precision antimicrobial treatments supported by the…
In mid-November, the AMR community welcomed the official introduction of Cures 2.0 by the bipartisan team of U.S.…
A new European consortia called PrIMAVeRA is developing an open-source, web-based platform combining mathematical models with…
Antibiotic Research UK (ANTRUK) announced that through its 2021 Small Research Grants / Career Development Awards…
A new analysis published by Kevin Outterson in the Health Affairs journal is estimating the appropriate…
AMR experts from Industry, SMEs, academia and public bodies discussed the impact of COVID-19 on AMR…
Investment climate for companies active in AMR was rather weak for a long time. However, over…
During the third day of the virtual 5th AMR Conference, the important role of governments and…
With INCATE a new public-private consortium was launched on 25 August to boost the development of…
We spoke with Aleks Engel from the Novo Holdings Repair Impact Fund, one of the speakers…
A group of experts has shown in an analysis that also in high-income countries patient access…
The Global AMR R&D Hub has published a report which highlights the mismatch between global needs…
CARB-X is organizing a webinar to celebrate its European projects and funding partners which have supported…
The Tripartite organizations (FAO, OIE, WHO) are conducting a public discussion survey on the development of…
The British cross-departmental project team behind Pathogen Surveillance in Agriculture, Food and the Environment (PATH-SAFE) brings…
British clinical trials expert Stephen Senn explains in a viewpoint essay on the GARDP website what…
The Global Fund grants US$37 million to FIND to advance tuberculosis prevention and control in India
FIND, the global alliance for diagnostics, and the Global Fund announced that FIND has been awarded…
A new London-Liverpool research alliance in UK will bring together academic and commercial sectors in a…
The European Centre for Disease Prevention and Control (ECDC) together with WHO Regional Office for Europe…
In an EURACTIV report, policymakers across the EU are being urged to consider the full range…
FIND has contributed to two major documents recently published by the WHO that represent major advances…
CEPI and Wellcome Trust have joined forces to further exploit the mRNA technology. To prepare for…
The Global AMR R&D Hub and ICARS announced a new partnership that will further strengthen their…
A 7-year, €185 million project called UNITE4TB was started by 30 partners from 13 countries as…
The JPIAMR’s Virtual Research Institute (JPIAMR-VRI) recently updated its digital platform to a large extent, now…
The London School of Hygiene & Tropical Medicine (LSHTM) has entered into a new partnership with…
Acurx Pharmaceuticals Incorporated, a clinical stage biopharmaceutical company committed to the development of a novel class…
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company for the development of novel…
The Global Coalition on Aging (GCOA) together with the Infectious Diseases Society of America (IDSA) have…
The EU’s Research and Innovation funding programme, Horizon Europe, has launched its research calls for 2021-2022…
AMR is a complex, multi-faceted problem that affects all of society and is driven by many…
The US Senate has reintroduced the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act…
BARDA have announced the creation of a new venture to develop and commercialize technologies and medical…
The 5-year programme will start in October 2021. Scientists from the Universities of Oxford, Ulster and…
The Nanotherapeutics hub and iiCON step up the UK’s infectious disease R&D pipeline. iiCON, led by…
CARB-X is awarding BioVersys, a pharmaceutical company headquartered in Basel, Switzerland, up to US$4.35 million in…
GARDP together with DNDi published a policy briefing statement at the 74th World Health Assembly. According…
CARB-X is awarding Swiss listed company Basilea Pharmaceutica International up to US $2.7m to develop a novel class…
Sandoz, a Novartis division, has announced plans to invest €150m and further strengthen its European antibiotics…
Up to $4.1 million in non-dilutive funding are being awarded by CARB-X to UK-based Summit Therapeutics. The capital…
BARDA is seeking proposals for a new Antibacterial Accelerator which is funded for the next ten…
End of April the General Assembly High-Level Interactive Dialogue on Tackling AMR took place as a…
US pharma company Pfizer acquired US-based biotech company Amplyx Pharmaceuticals for an undisclosed sum. The deal…
CARB-X is awarding GenomeKey (Genomics Labs Ltd.) in Bristol, UK, up to $3.0 million in non-dilutive…
US-based X-Biotix Therapeutics, focused on antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, will suspend its current antibacterial…
CARB-X is funding Phico Therapeutics, in Cambridge, UK, to develop a new intravenous engineered bacteriophage drug…
The WHO has published their updated analysis for the clinical and preclinical antibacterial product pipeline in…
Swiss BioVersys has received €20m from the European Investment Bank to push the development of new…
The European Commission launched an online public consultation on the Health Emergency Preparedness and Response Authority…
CARB-X is awarding up to US$2 million to the Jenner Institute, part of the University of…
Led by Wellcome Trust, a group of AMR funders has published the first guidance on strategies…
The Global AMR R&D Hub has published a study on national policy options to reward the…
CARB-X is funding the GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH),…
CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to…
CARB-X announced the investment of first grants to two German research teams from the German Helmholtz…
Researchers from the Helmholtz Centre for Infection Research (HZI) and the Lead Discovery Center GmbH (LDC)…
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) team could receive up to US$6.31 million if all…
Single intravenous dose Phase 1 study in healthy volunteers showed that EBL-1003 (apramycin) was safe and…
High-level global leaders group will advocate for urgent action to combat antimicrobial resistance across all sectors…
The Global AMR R&D Hub publishes its first report “The state of public and philanthropic investments…
The BEAM Alliance recently worked with Global Cause on the 2020 Antimicrobial Resistance campaign. The content…
BV100 is being developed for the treatment of serious hospital infections caused by Carbapenem resistant Acinetobacter baumannii…
CARB-X announced today it is awarding up to US$2.62 million to Polyphor AG (SIX:POLN), headquartered in…
